Cargando…

Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy

Immunotherapies have been accelerating the development of anti-cancer clinical treatment, but its low objective responses and severe off-target immune-related adverse events (irAEs) limit the range of application. Strategies to remove these obstacles primarily focus on the combination of different t...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wei, Peng, Anghui, Wu, Huajun, Quan, Yingyao, Li, Yong, Lu, Ligong, Cui, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779686/
https://www.ncbi.nlm.nih.gov/pubmed/33408716
http://dx.doi.org/10.3389/fimmu.2020.601497
_version_ 1783631383837540352
author Li, Wei
Peng, Anghui
Wu, Huajun
Quan, Yingyao
Li, Yong
Lu, Ligong
Cui, Min
author_facet Li, Wei
Peng, Anghui
Wu, Huajun
Quan, Yingyao
Li, Yong
Lu, Ligong
Cui, Min
author_sort Li, Wei
collection PubMed
description Immunotherapies have been accelerating the development of anti-cancer clinical treatment, but its low objective responses and severe off-target immune-related adverse events (irAEs) limit the range of application. Strategies to remove these obstacles primarily focus on the combination of different therapies and the exploitation of new immunotherapeutic agents. Nanomedicine potentiates the effects of activating immune cells selectively and reversing tumor induced immune deficiency microenvironment through multiple mechanisms. In the last decade, a variety of nano-enabled tumor immunotherapies was under clinical investigation. As time goes by, the advantages of nanomedicine are increasingly prominent. With the continuous development of nanotechnology, nanomedicine will offer more distinctive perspectives in imaging diagnosis and treatment of tumors. In this Review, we wish to provide an overview of tumor immunotherapy and the mechanisms of nanomaterials that aim to enhance the efficacy of tumor immunotherapy under development or in clinic treatment.
format Online
Article
Text
id pubmed-7779686
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-77796862021-01-05 Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy Li, Wei Peng, Anghui Wu, Huajun Quan, Yingyao Li, Yong Lu, Ligong Cui, Min Front Immunol Immunology Immunotherapies have been accelerating the development of anti-cancer clinical treatment, but its low objective responses and severe off-target immune-related adverse events (irAEs) limit the range of application. Strategies to remove these obstacles primarily focus on the combination of different therapies and the exploitation of new immunotherapeutic agents. Nanomedicine potentiates the effects of activating immune cells selectively and reversing tumor induced immune deficiency microenvironment through multiple mechanisms. In the last decade, a variety of nano-enabled tumor immunotherapies was under clinical investigation. As time goes by, the advantages of nanomedicine are increasingly prominent. With the continuous development of nanotechnology, nanomedicine will offer more distinctive perspectives in imaging diagnosis and treatment of tumors. In this Review, we wish to provide an overview of tumor immunotherapy and the mechanisms of nanomaterials that aim to enhance the efficacy of tumor immunotherapy under development or in clinic treatment. Frontiers Media S.A. 2020-12-21 /pmc/articles/PMC7779686/ /pubmed/33408716 http://dx.doi.org/10.3389/fimmu.2020.601497 Text en Copyright © 2020 Li, Peng, Wu, Quan, Li, Lu and Cui http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Li, Wei
Peng, Anghui
Wu, Huajun
Quan, Yingyao
Li, Yong
Lu, Ligong
Cui, Min
Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy
title Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy
title_full Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy
title_fullStr Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy
title_full_unstemmed Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy
title_short Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy
title_sort anti-cancer nanomedicines: a revolution of tumor immunotherapy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779686/
https://www.ncbi.nlm.nih.gov/pubmed/33408716
http://dx.doi.org/10.3389/fimmu.2020.601497
work_keys_str_mv AT liwei anticancernanomedicinesarevolutionoftumorimmunotherapy
AT penganghui anticancernanomedicinesarevolutionoftumorimmunotherapy
AT wuhuajun anticancernanomedicinesarevolutionoftumorimmunotherapy
AT quanyingyao anticancernanomedicinesarevolutionoftumorimmunotherapy
AT liyong anticancernanomedicinesarevolutionoftumorimmunotherapy
AT luligong anticancernanomedicinesarevolutionoftumorimmunotherapy
AT cuimin anticancernanomedicinesarevolutionoftumorimmunotherapy